Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma (SDC).

The procedures include screening, treatment and follow-up period. The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist (LHRHa) for up to 2 years.
Salivary Gland Neoplasm Duct
DRUG: Rezvilutamide|DRUG: Leuprolide Acetate
3-year disease-free survival (DFS), DFS is defined as the time from entry until disease recurrence or death, 36 months
3-year overall survival (OS), OS is defined as the time from entry until death due to any cause, 36 months, 60 months|3-year disease-specific survival (DSS), DSS is defined as the time from entry until disease-specific death, 36 months, 60 months|3-year distant-metastatic free survival (DMFS), DMFS is defined as the time from entry until distant metastasis or death, 36 months, 60 months|Adverse events, Evaluate adverse events utilizing CTCAE V5, 36 months|5-year disease-free survival (DFS), DFS is defined as the time from entry until disease recurrence or death, 60 months
The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma (SDC).

The procedures include screening, treatment and follow-up period. The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist (LHRHa) for up to 2 years.